A recent clinical trial has found that tofacitinib, the generic name for Xeljanz and Xeljanz XR, which are drugs indicated to help treat rheumatoid arthritis, psoriatic arthritis and colitis, may increase the likelihood of potentially fatal blood clots in the lungs, and increase the risk of mortality overall.
Xeljanz and Xeljanz XR (tofacitinib) are medications manufactured by Pfizer and approved for the treatment of adults with the following conditions:
Continue Reading about other open recalls from our Nail gun accident lawyer.
TheProductLawyers.com are helping tofacitinib victims with lawsuits on behalf of patients who experienced a venous thromboembolic event (VTE) such as a blood clot in the lungs (PE) or a blood clot in the deep veins of the body (DVT) after taking Xeljanz or Xeljanz XR for rheumatoid arthritis, psoriatic arthritis, or colitis
DVTs and PEs can be extremely dangerous, and even fatal and the labels for these medications do not presently warn of this risk.
We can help you explore your legal options, and may be able to seek compensation for your injuries, including medical expenses, lost wages, and pain and suffering. Get the justice you deserve.
TheProductLawyers.com is sponsored by a team of attorneys who have decades of experience in complex pharmaceutical litigation.
The Xeljanz label warns of many serious side effects but fails to mention death:
The current Xeljanz & Xeljanz XR labels do not warn of DVT events, but a recent post-marketing trial found an increased risk of PE in certain patients taking a 10 mg twice daily dose of Xeljanz.
Sudden trouble breathing
Shortness of breath
Chest pain (or back pain)
Coughing up blood
Skin that is clammy or bluish-colored
Swelling in the affected leg
Pain in your leg (often feeling like a cramp)
Discolored skin on the leg
Warmth in the area affected
Patients experiencing these symptoms should seek medical attention immediately. Consult your doctor before stopping any prescribed medication.
Learn more from our attorneys: Proton Pump Inhibitor Side Effects